Dr. Evan Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinnati, is leading clinical trials for a new drug candidate (REGN727) that may do a better job of lowering cholesterol than statins, and with fewer side effects. The New York Times and ABC News took notice last month.
Study results were published in a recent issue of The New England Journal of Medicine.
“About 5 to 10 percent of people can’t tolerate statins at all, and more can’t tolerate higher doses,” said Dr. Evan A. Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinnati and lead author of the drug trials. “It’s still early in development, but for them this is potentially a most promising alternative.”